[Denosumab--a new efficient osteoporosis therapy].
Denosumab is a new biological (monoclonal antibody) antiresorptive treatment of osteoporosis which is administrated as a subcutaneous 60 mg injection twice a year. Compared with placebo, three years of treatment increases bone mineral density by 6-9% and decreases the risk of vertebral and hip fractures by 68% and 40%, respectively, in postmenopausal women with osteoporosis. In men with iatrogenic hypogonadism due to prostate cancer, the risk of vertebral fractures is decreased by 62%. Side effects are few, but the treatment may increase risk of infections.